-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, the website of the Food and Drug Administration showed that the marketing application of the recombinant human papillomavirus bivalent (16/18 type) vaccine (yeast) of a subsidiary of Watson Bio (acceptance numbers: CXSS2000024, CXSS2000025, pre-filled The two dosage forms of syringe and vial) have entered the stage of "administrative approval" and are expected to be launched soon
.
It is understood that Watson Bio is a high-tech biopharmaceutical enterprise specializing in R&D, production and sales of biotech drugs such as human vaccines
.
As early as June 16, 2020, Watson Bio announced that the "recombinant human papillomavirus bivalent (16/18) vaccine (yeast)" independently developed by the company's holding subsidiary Shanghai Zerun has submitted a new drug production application , and was accepted by the State Food and Drug Administration on June 15
.
According to the announcement at that time, the bivalent HPV vaccine developed by Shanghai Zerun is used to prevent cervical cancer caused by HPV16 and 18 virus infection.
(HPV) in women
.
After the vaccination of the appropriate age group, the body can stimulate the body to produce immunity against HPV16 and 18 viruses, and can prevent cervical precancerous lesions caused by the above-mentioned virus infection, thereby preventing cervical cancer
.
HPV vaccine, short for cervical cancer vaccine, is mainly used to prevent cervical cancer in women
.
Studies have found that 99.
7% of cervical cancers are caused by infection with human papillomavirus (HPV).
There are currently more than 100 known types of HPV, of which at least 14 genotypes (ie high-risk types) are considered to cause cervical cancer.
cancer
.
At present, cervical cancer vaccines can be divided into bivalent, quadrivalent and nine-valent
.
The bivalent HPV vaccine protects against two high-risk types (HPV-16 and HPV-18), which are responsible for 84.
5% of cervical cancers in the Chinese population
.
The quadrivalent HPV vaccine adds two low-risk types, HPV-6 and HPV-11, to the bivalent HPV vaccine, which can reduce the occurrence of condyloma acuminatum.
The nine-valent HPV vaccine adds five high-risk types to the quadrivalent HPV vaccine.
type
.
There are 4 HPV vaccines on the market in China, namely Merck's 4-valent and 9-valent vaccine, GSK's bi-valent vaccine, and Wantai Bio's bi-valent vaccine (trade name: Xin Ke Ning)
.
It is reported that Xin Ke Ning's sales in China in 2020 will be approximately RMB 693 million
.
In 2021, GSK's bivalent vaccine sales will be $138 million, while Merck's quadrivalent and nine-valent vaccine (Gardasil/Gardasil 9) sales will be as high as $5.
673 billion, a year-on-year increase of 44%
.
If the domestic HPV vaccine of Watson Bio's subsidiary is successfully launched, it will be the second domestic bivalent HPV vaccine launched in China
.
The industry believes that replacing imports with its high cost performance will make a significant contribution to domestic women's health, and will also form a strong support for the company's performance
.
However, it should be noted that the current domestic HPV vaccine market is in a state of expansion as a whole, and the number of companies that want to enter the market is increasing.
For example, Jiangsu Ruike Bio has also deployed the bivalent HPV vaccine market in recent years
.
In the more competitive nine-price market, Bowei Bio and Xiamen Wantai have also entered Phase III and Phase II clinical trials respectively
.
Following this trend, as more and more HPV vaccines are developed and marketed, the competition in this market is expected to become more intense in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is understood that Watson Bio is a high-tech biopharmaceutical enterprise specializing in R&D, production and sales of biotech drugs such as human vaccines
.
As early as June 16, 2020, Watson Bio announced that the "recombinant human papillomavirus bivalent (16/18) vaccine (yeast)" independently developed by the company's holding subsidiary Shanghai Zerun has submitted a new drug production application , and was accepted by the State Food and Drug Administration on June 15
.
According to the announcement at that time, the bivalent HPV vaccine developed by Shanghai Zerun is used to prevent cervical cancer caused by HPV16 and 18 virus infection.
(HPV) in women
.
After the vaccination of the appropriate age group, the body can stimulate the body to produce immunity against HPV16 and 18 viruses, and can prevent cervical precancerous lesions caused by the above-mentioned virus infection, thereby preventing cervical cancer
.
HPV vaccine, short for cervical cancer vaccine, is mainly used to prevent cervical cancer in women
.
Studies have found that 99.
7% of cervical cancers are caused by infection with human papillomavirus (HPV).
There are currently more than 100 known types of HPV, of which at least 14 genotypes (ie high-risk types) are considered to cause cervical cancer.
cancer
.
At present, cervical cancer vaccines can be divided into bivalent, quadrivalent and nine-valent
.
The bivalent HPV vaccine protects against two high-risk types (HPV-16 and HPV-18), which are responsible for 84.
5% of cervical cancers in the Chinese population
.
The quadrivalent HPV vaccine adds two low-risk types, HPV-6 and HPV-11, to the bivalent HPV vaccine, which can reduce the occurrence of condyloma acuminatum.
The nine-valent HPV vaccine adds five high-risk types to the quadrivalent HPV vaccine.
type
.
There are 4 HPV vaccines on the market in China, namely Merck's 4-valent and 9-valent vaccine, GSK's bi-valent vaccine, and Wantai Bio's bi-valent vaccine (trade name: Xin Ke Ning)
.
It is reported that Xin Ke Ning's sales in China in 2020 will be approximately RMB 693 million
.
In 2021, GSK's bivalent vaccine sales will be $138 million, while Merck's quadrivalent and nine-valent vaccine (Gardasil/Gardasil 9) sales will be as high as $5.
673 billion, a year-on-year increase of 44%
.
If the domestic HPV vaccine of Watson Bio's subsidiary is successfully launched, it will be the second domestic bivalent HPV vaccine launched in China
.
The industry believes that replacing imports with its high cost performance will make a significant contribution to domestic women's health, and will also form a strong support for the company's performance
.
However, it should be noted that the current domestic HPV vaccine market is in a state of expansion as a whole, and the number of companies that want to enter the market is increasing.
For example, Jiangsu Ruike Bio has also deployed the bivalent HPV vaccine market in recent years
.
In the more competitive nine-price market, Bowei Bio and Xiamen Wantai have also entered Phase III and Phase II clinical trials respectively
.
Following this trend, as more and more HPV vaccines are developed and marketed, the competition in this market is expected to become more intense in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
